Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Shengdar Q. Tsai, PhD
Researcher Assistant Member
Experimental Hematology Division
St. Jude Children’s Research Hospital
MS 341, Room D3022B
262 Danny Thomas Place
Memphis, Tennessee, United States
Dr. Shengdar Q. Tsai is an assistant member in the Department of Hematology at St. Jude Children’s Research Hospital. He obtained his B.S. in Biochemistry and Chemistry from the University of Michigan, M.S. in Bioinformatics and Ph.D. in Functional Genomics from North Carolina State University. He was a postdoctoral research fellow and instructor at Massachusetts General Hospital and Harvard Medical School. Dr. Tsai has focused on developing methods for high throughput genome editing with TALENs, and defining and improving the genome-wide specificity of CRISPR-Cas nucleases. His long-term research goals are to develop safe and highly specific targeted genome-editing strategies for treating human genetic diseases.
His research interests include:
• Improving genomic methods to define and measure gene editing “off-target” effects
• Protein engineering of CRISPR-Cas nucleases for precise gene correction
• Regulation of DNA damage repair choice between error-prone non-homologous end-joining and precise homology-directed repair
• Genome-scale CRISPR-Cas screening for novel effectors of hematological diseases
• Developing novel strategies for allele-specific editing of genetic mutations that cause sickle cell disease and other hematological disorders
+myBinderRelated Content
-
Podcast: How New Gene Therapies for SCD May Impact Women’s FertilityAs we closed 2023, the Food and Drug Ad...
-
U.S. Government Awards Missouri Researcher $4.3 Million to Study Sickle Cell in Teens, AdultsThe National Institutes of Health (NIH) ...
-
New England Pediatric Sickle Cell ConsortiumThe New England Pediatric Sickle Cell Co...
-
The Sickle Cell Council of New MexicoThe Sickle Cell Council of New Mexico se...
-
Dr. Nina AndersonDr. Nina Anderson, completed her doctora...
-
The first two years of life in sickle cell anemia infants: A results of a comprehensive longitudinal studyInfancy is a critical time during which ...
-
Global Sickle Cell Disease Treatment Market 2019–2023| Evolving Opportunities with ADDMEDICA and Bristol-Myers Squ...The global sickle cell disease treatment...
